Resources and support for your eligible patients

CareASSIST offers access support for eligible patients prescribed Mozobil.

Access and Reimbursement

Access and Reimbursement

Assistance navigating the insurance process, including benefits investigations, claims assistance, and information about prior authorizations and appeals.

See what’s offered
Financial Assistance

Financial Assistance

Eligible patients may qualify to receive Mozobil at no cost.

Learn about eligibility
Resource Support

Resource Support

Information on independent support services for patients and caregivers, as well as product ordering and replacement information.

Find support

To learn more about CareASSIST

Dosing and Administration

Learn about the process of administering Mozobil.

access dosing schedule

About Mozobil

In clinical trials, Mozobil + granulocyte-colony stimulating factor (G-CSF) was shown to significantly reduce mobilization failures. Learn more about the clinical trials.1-3

see study results


  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2019.
  2. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  3. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.